Search Within

Jose T Baselga

  1. "Ana Bosch Campos"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Sloan Kettering Institute Postdocs (5)
  2. GSK Faculty (4)
  3. Breast Medicine Service (3)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (3)
  5. Department of Medicine (3)
  6. Molecular Pharmacology and Chemistry Program Faculty (3)

More Groups

People
  1. Ana Bosch Campos (6)
  2. Maurizio Scaltriti (5)
  3. Moshe Elkabets (3)
  4. Natasha Morse (3)
  5. Neal Rosen (3)
  6. Eneda Toska (2)

More People

Years
  1. 2015 (2)
  2. 2014 (3)
  3. 2013 (1)
Publications
  1. Science Translational Medicine (2)
  2. Cancer Research (1)
  3. Clinical Cancer Research (1)
  4. European Journal of Cancer (1)
  5. Science Signaling (1)
Publishers
  1. American Association for the Advancement of Science (3)
  2. American Association for Cancer Research (2)
  3. Elsevier Inc. (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adaptive and acquired mechanisms of resistance to PI3K inhibitors
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Will, M.; Li, Z.; Bosch Campos, A.; Schwartz, S.; Rodrik-Outmezguine, V. ; Berger, M.; Baselga, J.; Rosen, N.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
    Journal Article

    Bosch, A.; Li, Z.; Bergamaschi, A.; Ellis, H.; Toska, E.; Prat, A.; Tao, J. J.; Spratt, D. E.; Viola-Villegas, N. T.; Castel, P.; more...
    Science Translational Medicine (2015)

    Fulltext@MSK | Save
  • Novel regulation of estrogen receptor transcription by the PI3K pathway
    Meeting Abstract

    Toska, E.; Elkabets, M.; Bosch, A.; Litvin, O.; Scaltriti, M.; Baselga, J.
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy
    Journal Article

    Saura, C.; Bendell, J.; Jerusalem, G.; Su, S.; Ru, Q. H.; De Buck, S.; Mills, D.; Ruquet, S.; Bosch, A.; Urruticoechea, A.; more...
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
    Journal Article

    Tao, J. J.; Castel, P.; Radosevic-Robin, N.; Elkabets, M.; Auricchio, N.; Aceto, N.; Weitsman, G.; Barber, P.; Vojnovic, B.; Ellis, H.; more...
    Science Signaling (2014)

    Fulltext@MSK | Save
  • MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
    Journal Article

    Elkabets, M.; Vora, S.; Juric, D.; Morse, N.; Mino-Kenudson, M.; Muranen, T.; Tao, J.; Bosch Campos, A.; Rodon, J.; Ibrahim, Y. H.; more...
    Science Translational Medicine (2013)

    Fulltext@MSK | Save